BACKGROUND Iron deficiency may impair aerobic performance. This study aimed to determine whether treatment with intravenous iron (ferric carboxymaltose) would improve symptoms in patients who had heart failure, reduced left ventricular ejection fraction, and iron deficiency, either with or without anemia. METHODS We enrolled 459 patients with chronic heart failure of New York Heart Associatio...

A clinical case of successful surgical treatment in a patient with severe New York Heart Association (NYHA) functional class IIIIV heart failure, critical aortic stenosis, and extremely low left ventricular (LV) ejection fraction (EF) (16%) is presented. Aortic valve leaflet replacement was performed according to the Ozaki technique. The postoperative course uneventful discharged from hospital ...


 CADTH recommends that Verquvo be reimbursed by public drug plans for the treatment of chronic heart failure (HF) as an adjunct to standard care therapy if certain conditions are met.
 should only covered treat adult patients: whose is unable pump enough blood keep up with body’s needs because too weak (i.e., HF reduced ejection fraction); who considered symptomatic (e.g., slight lim...

Mavacamten is a first-in-class cardiac myosin modulator for HOCM, which genetic disorder of the sarcomere. This study assessed cost effectiveness mavacamten in addition to standard care (SoC) compared with SoC alone, as well disopyramide, myectomy, and septal ablation each SoC. A semi-Markov model was used over lifetime time horizon from healthcare sector perspective cycle length 4 weeks. Patie...

OBJECTIVE Advanced ischemic heart failure can be treated with surgical ventricular restoration (SVR). While numerous risk factors for mortality and recurrent heart failure have been identified, no plain predictor for identifying SVR patients with left ventricular damage beyond recovery is yet available. We tested echocardiographic wall motion score index (WMSI) as a predictor for mortality or p...

BACKGROUND Sudden death from cardiac causes remains a leading cause of death among patients with congestive heart failure (CHF). Treatment with amiodarone or an implantable cardioverter-defibrillator (ICD) has been proposed to improve the prognosis in such patients. METHODS We randomly assigned 2521 patients with New York Heart Association (NYHA) class II or III CHF and a left ventricular eje...

BACKGROUND The association of autonomic activation, left ventricular ejection fraction (LVEF) and heart failure functional class is poorly understood. OBJECTIVE Our aim was to correlate symptom severity with cardiac sympathetic activity, through iodine-123-metaiodobenzylguanidine (123I-MIBG) scintigraphy and with LVEF in systolic heart failure (HF) patients without previous beta-blocker treat...

BACKGROUND Preoperative characteristics may influence morbidity and mortality in patients undergoing coronary artery bypass grafting (CABG). The CABG Patch Trial was designed to assess the impact of prophylactic insertion of an implantable cardioverter-defibrillator in patients undergoing high-risk CABG. This database was used to investigate the influence of symptomatic congestive heart failure...

Thirteen male patients with NYHA class IV congestive heart failure refractory to conventional therapy were treated with oral fenoximone, a new imidazole compound with inotropic and vasodilator effects, for a mean duration of 11 weeks (range 2 to 34). On initial hemodynamic evaluation, the effects of oral fenoximone were comparable to those of the intravenous form and included a significant (p =...